Summary
Highlights
Prostate cancer is common in men, with many cases being lower-grade (stage one and two) that have a high survival rate after treatment. However, conventional wisdom incorrectly suggested that testosterone replacement therapy should be avoided, fearing it would exacerbate the cancer, like 'throwing gasoline on a fire'. Modern research, especially from Harvard, has debunked this myth, showing that testosterone does not reignite prostate cancer.
Leading prostate cancer surgeons now support the use of testosterone therapy for men with stage one and two prostate cancers. Patients can continue or immediately resume testosterone therapy, either during or after their definitive treatment. The literature strongly supports that returning to testosterone therapy after surgical removal of stage one and two prostate cancer carries no risk of recurrence related to the testosterone itself.
Emerging, though still preliminary, literature suggests that being hormonally balanced after prostate cancer surgery might even reduce the risk of recurrences. This potential benefit could be more significant than some chemotherapies. While this research is still evolving, it further underscores the safety and potential benefits of testosterone therapy for appropriate patients. For those seeking discussion on this topic, contacting their physician is recommended.